Scarica l'app Stockscreener
2.465
4.83%
-0.125
Dopo l'orario di chiusura:
2.47
0.005
+0.20%
Precedente Chiudi:
$2.59
Aprire:
$2.5268
Volume 24 ore:
2,436
Relative Volume:
0.36
Capitalizzazione di mercato:
$3.90M
Reddito:
$2.54M
Utile/perdita netta:
$-4.13M
Rapporto P/E:
-0.8964
EPS:
-2.75
Flusso di cassa netto:
$-4.11M
1 W Prestazione:
-20.99%
1M Prestazione:
-36.63%
6M Prestazione:
-45.46%
1 anno Prestazione:
-43.98%
Intervallo 1D:
$2.465
$2.5268
Intervallo di 1 settimana:
$2.26
$3.12
Portata 52W:
$2.26
$5.20
Xenetic Biosciences Inc Stock (XBIO) Company Profile
Nome
Xenetic Biosciences Inc
Settore
Industria
Telefono
781-778-7720
Indirizzo
945 CONCORD ST., FRAMINGHAM, MA
Confronta XBIO con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
XBIO
Xenetic Biosciences Inc
|
2.465 | 3.90M | 2.54M | -4.13M | -4.11M | -2.75 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.62 | 125.40B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.45 | 65.79B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
555.11 | 35.18B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
235.74 | 32.67B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
238.51 | 26.46B | 3.81B | -644.79M | -669.77M | -6.24 |
Xenetic Biosciences Inc Stock (XBIO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2020-01-08 | Iniziato | Maxim Group | Buy |
Xenetic Biosciences Inc Borsa (XBIO) Ultime notizie
Analyzing Takeda Pharmaceutical (NYSE:TAK) and Xenetic Biosciences (NASDAQ:XBIO) - Defense World
Xenetic Biosciences stock hits 52-week low at $2.7 By Investing.com - Investing.com South Africa
Xenetic Biosciences stock hits 52-week low at $2.7 - Investing.com
Short Interest in Xenetic Biosciences Inc (NASDAQ:XBIO) Decreases By 46.4% - Defense World
Xenetic partners with PeriNess for cancer study in Israel By Investing.com - Investing.com South Africa
Xenetic partners with PeriNess for cancer study in Israel - Investing.com Australia
Xenetic Biosciences, Inc. Announces Entry by Collaboration Partner into a Clinical Study Agreement to Advance Development of DNase Platform for the Treatment of Relapsed/Refractory Osteosarcoma and Ewing Sarcoma - standard-journal.com
Breakthrough DNase Treatment Takes Aim at Aggressive Childhood Cancers in New Trial - Stock Titan
Research Analysts Set Expectations for XBIO FY2025 Earnings - Defense World
Xenetic Biosciences (NASDAQ:XBIO) Earns “Neutral” Rating from HC Wainwright - Defense World
Analysts Offer Predictions for XBIO Q1 Earnings - Defense World
Xenetic Biosciences Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Xenetic Biosciences, Inc. Reports Full Year 2024 Financial Results - guardonline.com
Short Interest in Xenetic Biosciences Inc (NASDAQ:XBIO) Expands By 29.2% - Defense World
Xenetic Biosciences Strengthens Cancer Research Pipeline While Maintaining $6.2M Cash Position - Stock Titan
Xenetic Biosciences, Inc. SEC 10-K Report - TradingView
Xenetic Biosciences (XBIO) Expected to Announce Quarterly Earnings on Thursday - The AM Reporter
XENETIC BIOSCIENCES Earnings Preview: Recent $XBIO Insider Trading, Hedge Fund Activity, and More - Nasdaq
Xenetic Biosciences Inc expected to post a loss of 20 cents a shareEarnings Preview - TradingView
Xenetic Biosciences, Inc. Presents Positive Preclinical Data Underscoring the Potential of DNase I as an Adjunctive Treatment to Enhance Immunotherapeutic Responses - ACCESS Newswire
Breakthrough: New DNase I Treatment Supercharges CAR T Cell Cancer Therapy Success - StockTitan
Xenetic Biosciences (XBIO) Expected to Announce Earnings on Thursday - Defense World
Xenetic Biosciences Inc (NASDAQ:XBIO) Short Interest Update - Armenian Reporter
Xenetic Biosciences, Inc. to Present at the H.C. Wainwright 25th Annual Global Investment Conference - ACCESS Newswire
Xenetic Biosciences, Inc. Reports Full Year 2021 Financial Results and Provides Business Update - ACCESS Newswire
Xenetic Biosciences, Inc. Announces Reverse Stock Split of Common Stock - ACCESS Newswire
Xenetic Biosciences, Inc. Announces Closing of $6.0 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules - ACCESS Newswire
Xenetic Biosciences, Inc. Announces Abstract Accepted for Poster Presentation at the Society for Immunotherapy of Cancer (SITC) Spring Scientific 2025 Cell Therapy Meeting - Milton Daily Standard
Xenetic Biosciences Inc (NASDAQ:XBIO) Sees Large Decline in Short Interest - Armenian Reporter
Xenetic Biosciences Inc (NASDAQ:XBIO) Short Interest Down 21.4% in January - Defense World
Xenetic Biosciences, Inc. Presents at the H.C. Wainwright 26th Annual Global Investment Conference - ACCESS Newswire
Xenetic Biosciences Inc (NASDAQ:XBIO) Short Interest Up 1,920.0% in January - Defense World
Xenetic Biosciences, Inc. Announces Partner's Filing of Registration Dossier in Russia for Epolong Product Candidate That Utilizes Xenetic's PolyXen(R) Platform Technology - ACCESS Newswire
Xenetic Biosciences, Inc. to Participate in the Virtual Investor Innovation in Oncology Event - ACCESS Newswire
Xenetic Biosciences, Inc. Extends Research Agreement with the University of Virginia for the Advancement of its DNase-Based Oncology Platform - ACCESS Newswire
Xenetic Biosciences, Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update - ACCESS Newswire
Xenetic Biosciences, Inc. Reports Third Quarter 2024 Financial Results - ACCESS Newswire
Xenetic Biosciences, Inc. Releases Virtual Investor "What This Means" Segment - ACCESS Newswire
XBIOW (Xenetic Biosciences) Operating Income : $-4.36 Mil (TTM As of Sep. 2024) - GuruFocus.com
XBIOW (Xenetic Biosciences) Dividend Yield % : 0.00% (As of Jan. 13, 2025) - GuruFocus.com
XBIOW (Xenetic Biosciences) Cash Flow from Financing : $0.00 Mil (TTM As of Sep. 2024) - GuruFocus.com
Short Interest in Xenetic Biosciences Inc (NASDAQ:XBIO) Drops By 93.8% - Defense World
Xenetic Biosciences Advances Revolutionary DNase Cancer Treatment Platform with UVA Partnership - StockTitan
Xenetic Biosciences Extends Breakthrough Cancer Research Program with UVA Through 2025 - StockTitan
Xenetic Biosciences shareholders elect directors, approve auditor By Investing.com - Investing.com UK
Xenetic and PeriNess partner for cancer treatment trials By Investing.com - Investing.com Canada
Xenetic and PeriNess partner for cancer treatment trials - Investing.com
Xenetic Biosciences, Inc. Enters into Clinical Trial Services Agreement with PeriNess Ltd. to Accelerate Development of DNase I Oncology Program - AccessWire
Xenetic Biosciences Inc Azioni (XBIO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
10.70%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):